Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by luther30on May 01, 2019 9:09pm
275 Views
Post# 29698239

RE:RE:RE:IS ATE still thnking of doing a share reversal?

RE:RE:RE:IS ATE still thnking of doing a share reversal?They would do a RS to get their SP to over the 4 bucks that was previously mentioned to entice other investors.  Lots of people don't want to buy tickers under a buck no matter what the market cap is.



hausofstock wrote: Why does it matter if they RS?  ATE has a present market cap of $86,586,563.00 CAD @ $0.35/share and 243,905,811 shares outstanding.  If the company performs a reverse split the market cap does not change.  In fact uplisting to NASDAQ will allow institional investors like pension funds, mutual funds etc invest in the company.  Most are banned from investing in OTC or TSX.V.    In anycase they have voted to uplist and perform a ratio of 5 to 10 as of the last general meeting.  Here's hoping we get off the TSX.V and OTC and join the ranks of a real pharma company. 


Bullboard Posts